Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Mayhew

Interventional Pain Medicine Conway, SC Medical Doctor

NPI 1265439087 CMS profile 11365

2376 Cypress Cir Ste 300, Conway, SC 29526

Open in the dashboard

General payments

$883

47 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Mayhew of Conway, SC is reported in the CMS Open Payments database as having received $883 across 47 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 22nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $442 27
2024 General $136 7
2023 General $22 1
2022 General $51 3
2021 General $66 4
2020 General $124 2
2019 General $40 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Mayhew
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Scott Mayhew were reported at $442. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Scott Mayhew Interventional Pain Medicine median Middle half National median
2019 $40 $684 $216–$2,079 $163
2020 $124 $382 $122–$1,109 $114
2021 $66 $552 $167–$1,554 $132
2022 $51 $605 $187–$1,924 $149
2023 $22 $671 $195–$1,915 $160
2024 $136 $684 $206–$1,837 $164
2025 $442 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $205 6 payments
  2. Medtronic, Inc. $201 16 payments
  3. Nalu Medical, Inc. $82 4 payments
  4. AbbVie, Inc. $46 3 payments
  5. Novo Nordisk Inc $43 2 payments
  6. Painteq LLC $42 2 payments
  7. SPR Therapeutics, Inc $27 1 payment
  8. SI-BONE, Inc. $23 1 payment
  9. Globus Medical, Inc. $23 1 payment
  10. Hologic, LLC $22 1 payment
  11. Other $169 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $883 47 payments
Products named General payments · program years 2019–2025
  1. Proclaim Family of SCS IPGs $140 3 payments
  2. KYPHON EXPRESS II KYPHOPAK TRAY $113 8 payments
  3. Nalu Neurostimulation System $82 4 payments
  4. INCEPTIV $66 6 payments
  5. PAINTEQ $42 2 payments
  6. QULIPTA $31 2 payments
  7. UBRELVY $30 2 payments
  8. ETERNA $27 1 payment
  9. SPRINT PNS System $27 1 payment
  10. Senza $23 1 payment
  11. Other $315 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,510

Median for Interventional Pain Management: 1,220

Drug cost

$33,940

Median for Interventional Pain Management: $39,344

Branded share of claims

38.2%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 289 $7,672
Oxycontin Oxycodone Hcl Brand 12 $6,904
Gabapentin Generic 265 $4,028
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 208 $3,095
Fentanyl Generic 28 $1,982
Lidocaine Generic 34 $1,732
Tramadol Hcl Generic 140 $1,440
Morphine Sulfate Generic 44 $1,078
Morphine Sulfate Er Morphine Sulfate Brand 36 $727
Cyclobenzaprine Hcl Generic 89 $655

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$243,716

Of which drugs: $11,630

Medicare patients

279

Average age 73

Services billed

13,755

171 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Chronic kidney disease 28%
Diabetes 27%
Ischemic heart disease 23%
Depression 22%
Osteoporosis 22%
Cancer 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 83 218 $1,174
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 114 1,060 $802
Injection, methylprednisolone acetate, 1 mg J1010 Office 13 1,040 $101
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 80 1,030 $92

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $23
$23 — —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $21
$21 — —
KRYSTEXXA
  • Amgen Inc. $20
$20 — —
UBRELVY
  • AbbVie, Inc. $7
$7 — —
QULIPTA
  • AbbVie, Inc. $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

47 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record